Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland

ConclusionsOur results are in keeping with the phase III study findings: response rate, PFS and OS were similar to those reported in the phase III ANNOUNCE trial.
Source: Clinical Sarcoma Research - Category: Cancer & Oncology Source Type: research